Get the Stockscreener App
7.86
1.13%
-0.09
After Hours:
7.83
-0.03
-0.38%
Kamada Ltd stock is traded at $7.86, with a volume of 59,648.
It is down -1.13% in the last 24 hours and up +18.55% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$7.95
Open:
$7.94
24h Volume:
59,648
Relative Volume:
0.66
Market Cap:
$401.96M
Revenue:
$154.57M
Net Income/Loss:
$15.07M
P/E Ratio:
29.11
EPS:
0.27
Net Cash Flow:
$10.92M
1W Performance:
+8.86%
1M Performance:
+18.55%
6M Performance:
+29.92%
1Y Performance:
+55.64%
1-Day Range:
$7.795
$7.94
1-Week Range:
$7.1327
$8.20
52-Week Range:
$4.83
$9.155
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.86 | 401.96M | 154.57M | 15.07M | 10.92M | 0.27 |
|
RGC
Regencell Bioscience Holdings Ltd
|
21.73 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
157.23 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.97 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.00 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Should Value Investors Buy Kamada (KMDA) Stock? - Yahoo Finance
Kamada Confirms Continuous Global Business Operations and - GlobeNewswire
Kamada Ensures Global Operations Amid Middle East Tensions - TipRanks
Kamada confirms continuous business operations despite Middle East events - TipRanks
Kamada Confirms No Supply Disruptions: How Israeli Biotech Giant Safeguards Global Product Availability - Stock Titan
Kamada Reports Strong Q1 2025 Growth with Plasma Business Expansion and Key Milestones - citybuzz -
Implied Volatility Surging for Kamada Stock Options - Yahoo Finance
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in Combatting CMV in Organ Transplant Patients - citybuzz -
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM - FinancialContent
Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA) - Defense World
Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance
Alpha-1 Antitrypsin Deficiency Market: Epidemiology, - openPR.com
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong Factors - simplywall.st
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm - The Manila Times
HC Wainwright Issues Optimistic Outlook for Kamada Earnings - Defense World
Sidoti Csr Has Optimistic Outlook of Kamada FY2025 Earnings - Defense World
Kamada’s (KMDA) Buy Rating Reiterated at Benchmark - Defense World
Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript - MSN
Is Kamada (KMDA) Stock Undervalued Right Now? - Yahoo Finance
Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade - Yahoo Finance
Kamada Ltd’s Earnings Call Highlights Strong Growth and Expansion - TipRanks
Kamada (KMDA) Receives Reiterated Buy Rating from Benchmark | KM - GuruFocus
Kamada (KMDA) Receives Reiterated Buy Rating from Benchmark | KMDA Stock News - GuruFocus
Benchmark maintains Kamada stock Buy rating with $15 target By Investing.com - Investing.com Nigeria
Kamada: Q1 Earnings Snapshot - CT Insider
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo
Benchmark maintains Kamada stock Buy rating with $15 target - Investing.com
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Kamada Ltd. Reports Strong Q1 2025 Results - TipRanks
Kamada Q1 2025 Earnings Call Transcript - MarketBeat
Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Kamada Reports Strong First Quarter 2025 Financial Results with - GuruFocus
Kamada Reports Strong Q1 2025 Financial Results and Expands Plasma Operations - TipRanks
Kamada Reports Strong First Quarter 2025 Financial Results - GlobeNewswire
Inter Alpha Inhibitor Treatment Market Size in 7MM is expected - openPR.com
Kamada (KMDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
Kamada (NASDAQ:KMDA) Upgraded at Sidoti - Defense World
Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 - GlobeNewswire
Kamada Ltd. to report Q1 2025 financial results on May 14 - Investing.com Nigeria
Kamada to Release Q1 2025 Financial Results on May 14 - TipRanks
JPMorgan Chase & Co. Invests $67,000 in Kamada Ltd. (NASDAQ:KMDA) - Defense World
Kamada Launches Post-Marketing Research Program for CYTOGAM - TipRanks
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM® - GlobeNewswire
Major Breakthrough: Kamada Initiates 10 Clinical Studies to Transform Organ Transplant CMV Treatment - Stock Titan
Geode Capital Management LLC Raises Position in Kamada Ltd. (NASDAQ:KMDA) - Defense World
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.85%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):